On December 3, 2014, the US Food and Drug Administration (FDA) granted accelerated approval to blinatumomab (BLINCYTO®, from Amgen Inc.) – which had received breakthrough therapy designation a few ...
No takes yet. Share an insight, caveat, or question.
Yamazaki et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: